GMAB (Genmab A/S) Wutah bathi ing taun lumaku

Simbol resmi perusahaan genmab.com (GMAB)

Genmab A/S dominates the targeted oncology niche thanks to its exclusive antibody platform. The annual variable EPS illustrates the earnings per share trend, where the value -19.60 shows the current figure. The company leverages its patent moat to create breakthrough drugs and subsequently transfer rights to Big Pharma. This monetization strategy transforms scientific achievements into a steady stream of high-margin royalties.

GMAB (Genmab) riwayat Wutah bathi ing taun lumaku saka 04.07.2022 nganti 10.11.2026

Rincian metrik komprehensif lan analitis Genmab A/S (GMAB)

- rega saham lan prakiraan rega para ahli:
Rega Genmab AS|GMAB - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Kapitalisasi pasar Genmab Corp|GMAB - Nilai Total Perusahaan
- data kapitalisasi buku:
Nilai Akuntansi Saham Genmab|GMAB - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas genmab.com|GMAB - Total Aset Perusahaan
- rincian utang lan likuiditas:
Utang marang Modal Genmab A/S|GMAB - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal genmab.com|GMAB - Gunggung utang perusahaan|Utang-utang marang nilai buku Genmab Corp|GMAB - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Genmab|Rasio jangkoan perantara genmab.com
- indikator pendapatan resik lan kelipatan nilai:
GMAB - Penghasilan resik|Bathi resik mangsa ngarep Genmab A/S|GMAB - Pangali P/E|Pangali mangsa ngarep rega marang bathi Genmab Corp|GMAB - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Genmab Corp|GMAB - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Genmab|GMAB - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan genmab.com|GMAB - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Genmab A/S
Pambiji fundamental:GMAB Genmab AS
Produk mawa merek Genmab Corp

For Genmab A/S, the year-over-year relative change in EPS reflects the effectiveness of its strategy to evolve into a biotech behemoth by capitalizing on licensing royalties. This indicator measures the growth rate of net income per share, allowing investors to assess the real-time monetization of innovations and the fundamental resilience of the business regardless of market volatility.

Pesaing langsung

EXEL: Wutah bathi resik saben siji saham kanggo taun lumaku|NUVL (Nuvalent Corp) - Wutah bathi ing taun lumaku|Wutah bathi ing taun lumaku Kymera Corp|Wutah bathi saben saham ing taun lumaku IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Tambahing bathi saben saham ing taun lumaku|Wutah bathi ing taun lumaku ORIC (ORIC Pharmaceuticals, Inc.)|Owah-owahan bathi resik saben saham ing taun lumaku Relay Therapeutics Inc|Nurix Pharma - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Tyra Corp|VSTM (Verastem, Inc.) - Wutah bathi resik saben saham ing taun iki|GLUE: Wutah bathi resik saben siji saham kanggo taun lumaku|CGEM (Cullinan Therapeutics, Inc.) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Immuneering Corp IMRX|Wutah bathi ing taun lumaku CCCC|Black Diamond Therapeutics, Inc - Wutah bathi saben saham ing taun iki|Repare Therapeutics - Wutah bathi resik saben saham ing taun iki|Tambahing bathi saben saham ing taun lumaku PMVP|KPTI: Wutah bathi resik saben saham ing taun iki|Propanc Biopharma Inc - Wutah bathi resik saben siji saham kanggo taun lumaku|BGMS: Wutah bathi ing taun lumaku|Aadi Bioscience, Inc. - Tambahing bathi saben saham ing taun lumaku|ALRN (Aileron Therapeutics Inc) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Blueprint Medicines Corp BPMC|Wutah bathi saben saham ing taun lumaku GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Tambahing bathi saben saham ing taun lumaku